VIENNA, Va .–( Business WIRE)-VIENNA, VA BUSINESS WIRE)- CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy firm has announced today that it will present during the 13 13th annual LD Micro Main Event on December 15th, 2020 at 10:10 a.m. ET. Geert Kersten CEL-SCI’s Chief Executive Officer, Geert Kersten CEL-SCI is scheduled to speak to a live, virtual audience.
The LD Micro Main Event will have a fresh format. The event will feature companies who will present for 10 minutes then 10 minutes of Q&A with an investor panel and analysts.
About CEL-SCI Corporation
CEL-SCI believes that improving the immune system of a patient when it is in good health could have the highest effect on survival. So, in the phase 3 study CEL-SCI has treated patients newly diagnosed with advanced squamous-cell cancer of the neck and head using the experimental product MultikinePrior to when they underwent treatment with radiation, surgery or chemotherapy. This method is different. Many other cancer immunotherapies are only administered after conventional treatments have been tried but failed. Multikine (Leukocyte Interleukin Injection) is a treatment that has been granted Orphan Drug designation from the FDA for neoadjuvant treatment for patients suffering from squamous cell cancer (cancer) that affects the neck and head.
CEL-SCI considers that the Phase 3 study is the largest Phase 3 study in the world that addresses cancer of the neck and head. According to the study’s protocol newly diagnosed patients suffering from advanced primary squamous cells cancer of the head or neck were treated using the Multikine treatment protocol immediately after diagnosis, and prior to getting an operation known as the Standard of Care (SOC) that includes radiation, surgery or radiochemotherapy. Multikine was designed to aid to the body’s defense body “see” the tumor at an age that the body’s immune system is in good health and is believed to be more in a position to launch an attack against the cancer. The purpose of treatment using Multikine is to enhance the immune system before SOC to fight the cancer. This phase 3 trial is completely enrolling 928 patients, and the final patients were treated on September of 2016. To establish the overall survival benefits the study requires CEL SCI for 298 events have occurred within the two main groups of comparator. This milestone in the study occurred in the latter part of April 2020. The study is in the process of statistical analysis.
Its LEAPS technology is currently being developed for rheumatoid arthritis , and as a possible treatment for COVID-19-related infections. The company operates within Vienna, Virginia, and near or in Baltimore, Maryland.
It contains forward-looking information that are within the meaning of section 27A under the Securities Act of 1933, as modified as amended, in addition to Section 21E of the Securities Exchange Act of 1934 with respect to statements regarding Multikine and the clinical trial in Phase 3 of Multikine for patients suffering from advanced primary squamous cells of the neck and head. In this press release those words “intends,” “believes,” “anticipated,” “plans” and “expects,” and similar phrases, are meant to indicate forward-looking statements. These statements are subject uncertainties and risks which could cause the actual results to differ significantly from the ones anticipated. Factors that could lead to or contribute to the existence of such deviations include, for example, the inability to replicate the clinical trials or other results from clinical studies and timely development of possible products that are demonstrated to be secure and efficient, obtaining required regulatory approvals, challenges in the manufacturing of or preparing any possible products, the inability of raising the capital required and the risks identified from time date in the filings of CEL-SCI with the Securities and Exchange Commission, including , but not the annual report on Form 10-K/A for the year that ended on September 30 in 2019. The Company is not under any obligation to make public the outcome of any changes to these forward-looking assertions that may be made in order to reflect events or conditions that occur after the date hereof or in response to the impact of events that are not anticipated.
*Multikine (Leukocyte Interleukin injection) is the name of the trademark CEL-SCI is registered to use for the experimental treatment, and the proprietary brand name will be subject to FDA examination in connection with CEL-SCI’s anticipated future regulatory submission to be approved. Multikine is not granted a license or approval to be sold, bartered or trade by FDA nor any other agency. Additionally, its safety and effectiveness have not been confirmed for any purpose. Furthermore, no conclusive conclusion could be drawn from early-phaseclinical trials data that involve the treatment investigation Multikine. Further research is needed and early-phase clinical trial findings need to be confirmed during the clinical trial in Phase 3 of this therapy is underway.